Drugs / VON WILLEBRAND FACTOR HUMAN
VON WILLEBRAND FACTOR HUMAN
also known as
von Willebrand factor · Human von willebrand factor · Von willebrand factor human component of voncento · Von willebrand factor human component of voncento von willebrand factor · Von willebrand factor human component of wilate · Von willebrand's factor · vWF · vWFC · +1 more
Protein / enzyme biologic targets VWF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00004667 | Oct 1993 → ? | von Willebrand disease (hereditary or acquired) | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03613584 Comparator | Apr 2018 → Mar 2021 | acquired von willebrand syndrome | Tirol Kiniken GmbH | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-06-06 | Groupe Lfb | Regulatory LFB announces the extension of the indications of WILFACTIN® / WILLFACT® to the entire paediatric population in the European Union groupe-lfb.com ↗
LFB announced today the extension of the indications of WILFACTIN® / WILLFACT® to the entire paediatric population of the European Union and United Kingdom. |
| 2010-12-20 | Sobi, Inc. | Regulatory Swedish Orphan Biovitrum to increase the availability of Willfact® to von Willebrand patients as LFB BIOMEDICAMENTS has received additional European regulatory approvals sobi.com ↗
Swedish Orphan Biovitrum (STO: SOBI) today announced that LFB BIOMEDICAMENTS (LFB) has received a positive review of Willfact(®) under a Mutual Recognition Procedure (MRP), by the German regulatory authority (the Paul-Ehrlich-Institute) representing the other European authorities involved in the procedure. |
All press releases naming this drug 3 releases
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VON WILLEBRAND FACTOR HUMAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298126 ↗ |
| Known as | Human von willebrand factor | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298126 ↗ |
| Known as | von Willebrand factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004667 ↗ |
| Known as | Von willebrand factor human component of voncento | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298126 ↗ |
| Known as | Von willebrand factor human component of voncento von willebrand factor | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298126 ↗ |
| Known as | Von willebrand factor human component of wilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298126 ↗ |
| Known as | Von willebrand's factor | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298126 ↗ |
| Known as | vWF | “degradation of high molecular weight (HMW) of von Willebrand factor (vWF) multimers occur leading to an acquired von Willebrand disease.” NCT03613584 ↗ |
| Known as | vWFC | “A continuous treatment with von Willebrand factor concentrate (vWFC) may restore the multimers and bleeding can be avoided.” NCT03613584 ↗ |
| Known as | Willfact | “Administration of Von Willebrand Factor Concentrate (Willfact®, LFB France) in Adult Patients During Extracorporeal Membrane Oxygenation” NCT03613584 ↗ |
| Action | Restore | “A continuous treatment with von Willebrand factor concentrate (vWFC) may restore the multimers and bleeding can be avoided.” NCT03613584 ↗ |
| Modality | Protein / enzyme biologic | “new von Willebrand factor concentrate” NCT00004667 ↗ |
| Target | VWF | “von Willebrand factor exogenous protein” CHEMBL4298126 ↗ |